From the Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Saarland, 66424, Homburg, Germany.
Hypertens Res. 2023 Sep;46(9):2159-2167. doi: 10.1038/s41440-023-01359-y. Epub 2023 Jul 13.
Arterial hypertension is associated with increased morbidity and mortality and research in the field is highly dynamic. This summary reviews the most important clinical trials published in 2022 and early 2023. Findings on new pharmacological approaches to treat resistant hypertension are presented and new knowledge about the optimal timing of the antihypertensive medication intake is discussed. It is focused on optimal blood pressure treatment targets and the problem of treatment and guideline inertia is acknowledged. Information about pregnancy-related hypertension is presented and blood pressure control following percutaneous thrombectomy after ischemic stroke is discussed. Finally, novel clinical data on device-based approaches to treat hypertension are summarized. The hypertension trials update summarizes the most important clincal trials on hypertension research in 2022 and early 2023. CTD - chlorthalidone, CV - cardiovascular, HCT - hydrochlorothiazide, SBP - systolic blood pressure, RDN - renal denervation *depicts systolic blood pressure only.
高血压与发病率和死亡率的增加有关，该领域的研究非常活跃。本总结回顾了 2022 年和 2023 年初发表的最重要的临床试验。介绍了治疗耐药性高血压的新药物治疗方法的研究结果，并讨论了关于最佳降压药物摄入时机的新知识。重点是最佳血压治疗目标以及治疗和指南惯性的问题。还介绍了与妊娠相关的高血压信息，并讨论了缺血性卒中后经皮血栓切除术的血压控制情况。最后，总结了高血压治疗设备的新临床数据。高血压试验更新总结了 2022 年和 2023 年初高血压研究的最重要临床试验。CTD-氯噻酮，CV-心血管，HCT-氢氯噻嗪，SBP-收缩压，RDN-肾去神经支配*仅表示收缩压。
